About Arch Therapeutics
Arch Therapeutics is a company based in Natick (United States) founded in 2006. Arch Therapeutics has raised $320 thousand across 13 funding rounds. Arch Therapeutics offers products and services including AC5 Advanced Wound System, AC5 Topical Hemostat, and AC5-G. Arch Therapeutics operates in a competitive market with competitors including Abyrx, Biom'Up, Prytime Medical Devices, Endomedix and United Health Products, among others.
- Headquarter Natick, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Arch Therapeutics Inc
-
Annual Revenue
$75.72 K (USD)383.8as on Sep 30, 2023
-
Net Profit
-$6.98 M (USD)-32.35as on Sep 30, 2023
-
EBITDA
-$5.04 M (USD)11.62as on Sep 30, 2023
-
Total Equity Funding
$320 K (USD)
in 13 rounds
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Arch Therapeutics
Arch Therapeutics is a publicly listed company on the OTC with ticker symbol ARTHQ in USA, operating in the Distribution services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Arch Therapeutics
Arch Therapeutics offers a comprehensive portfolio of products and services, including AC5 Advanced Wound System, AC5 Topical Hemostat, and AC5-G.
Self-assembling technology for managing wounds in surgery and trauma.
Product to control bleeding during medical procedures.
Agent for gastrointestinal bleeding and submucosal lifting.
People of Arch Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Arch Therapeutics
Arch Therapeutics has successfully raised a total of $320K across 13 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Arch Therapeutics
Investment portfolio details for Arch Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Arch Therapeutics
Detailed financials for Arch Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Arch Therapeutics Comparisons
Peer comparison for Arch Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Arch Therapeutics
Arch Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abyrx, Biom'Up, Prytime Medical Devices, Endomedix and United Health Products, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Hemostatic bone putty is developed for surgical bone bleeding control.
|
|
| Locked | Locked | Locked |
Hemostatic products for surgical applications are developed using collagen-based materials.
|
|
| Locked | Locked | Locked |
Developer of minimally invasive large vessel occludes for hemorrhage control in trauma patients
|
|
| Locked | Locked | Locked |
Hydrogel solutions for surgery and wound care are developed.
|
|
| Locked | Locked | Locked |
Medical device for hemostasis during surgical procedures is provided.
|
|
| Locked | Locked | Locked |
Absorbable surgical sealants and hemostats are developed for leakage prevention.
|
Detailed competitors of Arch Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Arch Therapeutics
Complete news archive for Arch Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Arch Therapeutics
Arch Therapeutics was founded in 2006 and raised its 1st funding round 1 year after it was founded.
Arch Therapeutics is headquartered in Natick, United States. It is registered at Natick, Massachusetts, United States.
Arch Therapeutics is a funded company, having raised a total of $320K across 13 funding rounds to date.
Annual revenue of Arch Therapeutics is $75.72K as on Sep 30, 2023.
Arch Therapeutics was founded in 2006 and is headquartered in Natick, United States. Operations center on biotechnology, with development of a synthetic peptide-based hemostatic device known as AC5 for use in minimally invasive and open surgical procedures. The transparent, biocompatible material is applied to achieve rapid bleeding control and fluid leakage prevention, particularly in irregular wound sites. As of January 2016, human trials had not been conducted.
Arch Therapeutics's top competitors include Prytime Medical Devices, Biom'Up and United Health Products.
Arch Therapeutics offers AC5 Advanced Wound System, AC5 Topical Hemostat, and AC5-G.
Yes, Arch Therapeutics is publicly traded on OTC under the ticker symbol ARTHQ.
The ticker symbol of Arch Therapeutics is ARTHQ on OTC.